Clinical trial NCT01056692: OC000459 Bronchial Allergen Challenge
Official title: A Phase II Study of oc000459 in Subjects With Allergic Asthma; a Randomised, Double Blind, Two Way Balanced Crossover Comparing oc000459 With Placebo
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Bronchial Asthma
Keywords: Asthma
bronchial allergen challenge
sputum eosinophiilia
Lead sponsor: Oxagen Ltd
Sponsor class: INDUSTRY
Collaborators: name: Medicines Evaluation Unit, Manchester, UK
name: King's College Hospital NHS Trust
First posted: 2010-01-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: OC0000459 reduces inflammation in the tissues in response to allergic stimuli in patients with asthma. This clinical trial, in mildly asthmatic patients, studies the effects of OC000459 and placebo on the asthmatic response to two known stimulants of the asthmatic response in the lungs, namely cat hair, pollen or house dust mite and methacholine.


Eligibility criteria: Inclusion Criteria:

* Known history of asthma (intermittent wheezing, cough, dyspnoea responsive to inhaled short acting beta agonists).
* FEV1 \>65% of predicted on at least two occasions at screening.
* At the screening allergen challenge, a decrease in FEV1 of ≥20% in the early asthmatic reaction and of ≥15% in the LAR to allergen on 3 separate occasions between 3-10hrs post allergen, 2 of which must be consecutive.
* No steroid usage in the past 12 weeks.
* Testing positive to skin prick challenge with at least one of the following allergens: house dust mite, pollen or cat hair within the previous 12 months.
* Non smokers for a minimum of 6 months; less than 10 pack year history.

Exclusion Criteria:

* Respiratory tract pathology other than allergic asthma.
* Lower respiratory tract infection within 4 weeks prior to an allergen challenge.
* Receipt of prescribed or OTC medication other than paracetamol or short acting inhaled beta agonists within 14 days of screening or of the first day of each dosing period.

Primary outcomes:
measure: The primary endpoint is the diminution in the late asthmatic response to bronchial allergen challenge as measured by the AUC and the maximum of percentage reductions in FEV1 between 3 and 10 hours after allergen challenge.
timeFrame: Primary outcome is measured after 15 days of treatment with active or placebo
Secondary outcomes:
measure: Secondary biological activity endpoints include the diminution of the early asthmatic response to bronchial allergen challenge sputum eosinophilia, the methacholine PC20 after allergen challenge and exhaled NO pre- and post-allergen.
timeFrame: These measures are examined after 15 days of treatment with either active or placebo
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: King's College London School of Medicine
city: Manchester
country: United Kingdom
facility: Medicines Evaluation Unit
Study officials:
affiliation: Medicines Evaluation Unit, Manchester, UK
name: David Singh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Singh D, Cadden P, Hunter M, Pearce Collins L, Perkins M, Pettipher R, Townsend E, Vinall S, O'Connor B. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013 Jan;41(1):46-52. doi: 10.1183/09031936.00092111. Epub 2012 Apr 10.